In the cover paper of this week's issue of Oncotarget (Volume 12, Issue 10), titled, "Inhibitory effects of Tomivosertib in acute myeloid leukemia," researchers based out of Chicago, Illinois, U.S., from Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, and Jesse Brown Veterans Affairs Medical Center conducted a new study to assess the efficacy of Tomivosertib to regulate the eIF4E binding protein in AML.
In this study, the researchers purchased Tomivosertib (and Venetoclax) from TargetMol. They cultured AML cell lines, used clonogenic leukemic progenitor assays in methylcellulose, cell viability assays, cell lysis and immunoblotting, co-immunoprecipitation assays, plasmids and transfections, and conducted proteomics immunoprecipitation analysis using liquid-chromatography-tandem mass spectrometry, gene annotation and protein function enrichment analysis, and statistical analysis.
“We demonstrate that Tomivosertib suppresses eIF4E phosphorylation in AML cells and decreases leukemic cell survival and proliferation.”
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27952
DOI - https://doi.org/10.18632/oncotarget.27952
Full text - https://www.oncotarget.com/article/27952/text/
Correspondence to - Leonidas C. Platanias - l-platanias@northwestern.edu
Keywords - MNK, Tomivosertib, acute myeloid leukemia, eIF4E
About Oncotarget
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957
